Improved Q3 Order Performance
Q3 2025 saw mid-single-digit percentage organic bookings growth, with significant improvements in the academic government market segment and biopharma orders. The book-to-bill ratio surpassed 1.0 for the first time in several quarters.
Successful Cost Savings Initiatives
Bruker's cost savings initiatives are on track towards the high end of the $100 million to $120 million target for 2026, expected to deliver significant margin expansion and double-digit EPS growth.
Strength in Diagnostics and Spatial Biology
The diagnostics segment, particularly the ELITech molecular diagnostics franchise, showed strong growth. Spatial biology solutions also gained traction with biopharma and academic customers.
Encouraging Signs from China
Organic scientific instruments orders in China increased by a double-digit percentage year-over-year in Q3 2025, with early signs of stimulus funding being dispersed.